VTAK earnings analysis
What we found in VTAK's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Q2 2026 revenue increased to $1.019 million from $212 thousand year over year as the FLYTE acquisition added $749 thousand of aviation service revenue, but service costs of $899 thousand produced negative service gross profit and consolidated gross margin of only 9.6%. Operating cash use was $5.657 million for the first six months, and management stated that $2.1 million of cash as of August 11, 2026 would not fund current operations, resulting in substantial going-concern doubt. The company also faces potentially extraordinary dilution of approximately 96.0 million shares from preferred stock versus 14.4 million common shares outstanding.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue surged on FLYTE consolidation
- Total revenue increased $807 thousand year over year to $1.019 million in Q2 2026 from $212 thousand, driven primarily by $749 thousand of newly consolidated FLYTE service revenue. Revenue also increased $136 thousand sequentially from $883 thousand implied by Q1 2026 six-month and quarterly data?
- LockeT growth offset VIVO weakness
- Product revenue rose $58 thousand year over year to $270 thousand. LockeT revenue increased $75 thousand, while VIVO System revenue decreased $17 thousand because of fewer customers.
- Service costs compressed gross margin
- Consolidated gross profit was approximately $98 thousand on $1.019 million of revenue, producing a gross margin of approximately 9.6%, versus $198 thousand and 93.4% in Q2 2025. The deterioration reflected $899 thousand of service costs against $749 thousand of service revenue.
- Financing offset substantial cash burn
- Six-month operating cash use increased to $5.657 million from $4.601 million in the prior-year period. Financing activities provided $8.364 million, including $6.9 million of equity-classified proceeds, while investing activities used $2.152 million.
- Prior-year acquisition charges did not recur
- The company recorded no acquired in-process R&D expense in the first six months of 2026, versus $1.967 million in the prior-year period, and six-month net loss was $5.0 million versus $9.5 million in 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern and liquidity risk
- Management concluded there is substantial doubt about the company’s ability to continue as a going concern for one year after issuance. Cash was $0.6 million at June 30, 2026, six-month operating cash use was $5.657 million, and management said cash of $2.1 million as of August 11, 2026 was insufficient to fund current operations.
- Extreme potential dilution
- Outstanding preferred stock could convert into approximately 96,041,615 common shares at a $0.23 conversion price, compared with 14,391,944 common shares outstanding as of August 10, 2026. The filing states this represents approximately 6,673% of current shares and could reduce existing holders to less than approximately 13.0% of post-conversion shares.
- FLYTE operator costs threaten profitability
- The newly disclosed FLYTE aviation business relies on third-party operators for substantially all brokerage revenue and faces higher operator costs and capacity constraints. In Q2 2026, service revenue was $749 thousand while service cost was $899 thousand, resulting in negative service gross profit of approximately $150 thousand before corporate expenses.
What they reported.
What the company itself reported, taken out of the document.
- Gross margin
- 9.6%
- Segment
- Cardiac electrophysiology: product revenue $270 thousand for Q2 2026, versus $212 thousand in Q2 2025; six-month revenue was $518 thousand versus $355 thousand.
- Segment
- Private aviation charter services: service revenue $749 thousand for Q2 2026 and $933 thousand for the six months ended June 30, 2026; no comparable 2025 service revenue.
What they said about what is next.
No explicit numeric revenue or EPS guidance was provided. Management stated that cash of $2.1 million as of August 11, 2026 will not be sufficient to fund current operations and that additional capital will be required over the next 12 months.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 18, 2026
- Catheter Precision, Inc. reported Q4 2025 results with a revenue of $238 million, a significant year-over-year increase of 95%. However, the company faced persistent operational losses reflected in a diluted EPS of…
- 10-K · April 30, 2026
- Catheter Precision, Inc. continues to experience significant revenue growth, reporting a total revenue of $238 million for Q4 2025, marking a 95% year-over-year increase despite registering a negative EPS of -2.88. The…
- 10-K · March 31, 2026
- The 10-K shows a sharp top-line recovery: revenue rose to $819,000 in 2025 from $420,000 in 2024 (≈95% YoY) driven by product sales growth. Product and technology development activity accelerated (VIVO used in >1,000…
- 10-Q · August 11, 2025
- Q2 2025 revenue increased to $212,000 from $93,000 a year ago, and GAAP EPS improved to $(0.38) from $(5.57) in Q2 2024. Despite top-line growth and a high gross margin (93.4%), operating loss widened to $(4,686) and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing VTAK makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever